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CHAPTER 1: INTRODUCTION
The kidneys, located in the posterior wall of the body, perform many functions that the
body relies upon to survive. Such processes include waste excretion, chemical balance (e.g.
electrolyte and acid-base balance, Calcium-Phosphate metabolism), regulation of blood pressure,
in addition to fluid balance [44]. The kidneys’ complex structure contains a plethora of tissue
layers and permeable membranes and vessels in a way where filtration, absorption, and secretion
are some of the main objectives the kidneys are used for. Blood circulation through the kidneys
as well as excretion of waste products from it through urine is essentially the paths that allow for
the aforementioned functions to occur [44]. The anatomy of the kidneys (figure 1.0) include
complex parts such as the nephrons and glomerulus within the cortex, as well as the medulla,
pyramid, pelvis, and ureter that allows waste-carrying urine to flow on to the bladder to be
excreted from the body [44]. The nephrons provide the structural and functional units of the
kidneys where the aforementioned processes allow urine formation to occur [44].

Any

disruption or abnormalities in any of these processes can show signs of damage or failure to the
kidneys [44].
The circulation of blood flow through the kidneys is where the reabsorption, secretion,
and excretion occurs [44]. Since these steps take place within the nephron via afferent and
efferent arterioles, reabsorption of certain products (e.g. water, salts, sugars) can return to
circulation within the body [44]. Secretion can occur to return certain components such as acids,
minerals, urea, and byproducts of drugs in order to return to the renal tubule to be excreted in
urine while other components reach circulation via the veins [44]. The glomerular capillaries are
porous, allowing fluids that contain those byproducts mentioned previously (and proteins if there
are underlying issues) [44]. The Bowman’s Capsule that contains the glomeruli, essentially
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carrying the glomerular filtrate, occurs at a rate (glomerular filtration rate) affected by blood
pressure [44]. Membranes inside the capsule filters the entering plasma so that certain molecules
such as water and solutes can pass through, whereas, larger molecules like proteins could
problematic and cause for concern [44]. Surface area available for filtration is adjustable due to
blood pressure changes [44]. Normal GFR is designated between 120-125 mL/min in normal,
adult kidneys, and rates below that range could be problematic considering normal amounts of
filtrate are not being processed [44].
Filtration in the remaining renal tubules (e.g. proximal, loop of Henle, distal) is
responsible for secreting and reabsorbing certain contents in order to maintain a chemical
balance within the blood affected by blood pressure [44]. This entails the reabsorption of
molecules such as sodium ions, hydrogen ions, phosphates, bicarbonate, and water, as well as the
secretion of urea, ammonia, and other toxic substances to be excreted in urine [44]. These two
features allow the kidneys to help maintain fluid balance, electrolyte balance, control blood pH,
eliminate nitrogenous wastes, as well as disposal of certain drugs and metabolites [44]. Keeping
blood pH intact is necessary considering environmental conditions due to pre-existing conditions
(e.g. diabetes, severe chloride depletion, lactic acid buildup) can either severely raise or lower
those levels resulting in acidosis (low pH) and alkalosis (high pH) [44]. Waste management is
especially important considering buildup of substances, such as urea, can affect kidney function
in terms of a negative impact on GFR [44], [12].
Kidney failure is a progressive and debilitating disease that affects many Americans.
Numerous factors negatively affect the kidneys’ ability to function as they work to filter
byproducts of multiple origins (e.g. metabolic wastes, drugs, fluid balance). The repeated abuses
often overload the kidneys, reduce their efficacy, and may result in their failure altogether [1].
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Certain conditions such as metabolic syndrome, hypertension, and diabetes, are recurrent with
chronic kidney disease (CKD) with the latter being the most prevalent of causative factors [2].
Over time, the kidneys can stop functioning during CKD which can eventually lead to what is
known as end stage renal disease (ESRD) [1]. Prevalence of ESRD has risen in the United States
from 1980 until 2010. The adjusted rate of these prevalent cases has risen in 2010 to 1,763 per
million populations, up 21 percent higher than 10 years prior (Figure 1.1).
Among the ESRD population, approximately 400,000 people within that group are
seeking dialysis treatment, including 33% that are African American [2]. ESRD continues to be
the highest for African Americans compared to other ethnicities [2], [3]. However, between
mortality and survivability, certain factors show the African American dialysis patients have a
greater survival rate than whites (e.g. body mass, lipid profiles) [2].
CKD is characterized by a decrease in kidney function over a given period of time [1].
The rate at which blood flows into the kidneys must be determined using the Modification of
Diet in Renal Disease (MDRD) formula [4] resulting in assigning a numerical value. Again, this
rate is known as the glomerular filtration rate (GFR), the rate at which blood flows into the
vessels of the kidneys (glomeruli) through filters so that byproducts are separated and excreted
out through urine [1]. The GFR levels (between 15 and 90 mL/min/1.72m2) that define the stages
of CKD are also seen in Figure 1.2 [5]. ESRD occurs after stage 5, when there is an irreversible
loss of function and renal replacement therapy is required [1]. As this is examined further,
reabsorption and secretion steps involving the filtrate through the glomeruli and tubules can
drastically reduce or not occur at all due to failed kidneys [44]. Eventually, the inability to form
urine would be a clear indication of problematic situation among the kidneys where waste
products cannot be eliminated which are returned to the blood [44]. The overlaying effect would
	
  

	
  

4	
  

contribute to a negative impact on homeostasis involving factors such as electrolyte balance,
blood pH, and fluid balance, as aforementioned.
Aside from kidney transplantation, alternative forms of treatment modalities are
peritoneal dialysis and hemodialysis. With peritoneal dialysis, the use of blood vessels in the
abdominal lining, or peritoneum, fills in the kidneys aided by a dialysate [4]. This dialysate is
essentially a cleansing fluid that aids in the filtration of waste products as fluid passes through
the peritoneal space [4] that is delivered via a surgically implanted catheter inside the abdomen.
Hemodialysis requires the use of a dialysis machine that functions as an artificial kidney, or
dialyzer, to filter the metabolic waste products, salts, and fluids from the blood [6]. This requires
access to the blood vessels by way of a minor surgical procedure via the patients arm in what
appears to be two incisions: one for removal and cleansing of the blood and the other to return
the cleaned blood back into the patient’s system [4], [6].
Based on current research, causes of CKD and ESRD stem from multiple factors: drug
use, hypertension, and diabetes. Drug use can lead to nephrotoxic effects on intra-glomerular
blood flow, cell injury via cytotoxicity, and crystal induced obstruction of the vessels [7].
During hypertension, high blood pressure forces the heart to work harder over time, thereby
damaging blood vessels throughout the body, including blood vessels within the kidneys [8].
Those inflicted with diabetes have higher levels of blood sugar that causes the kidney filters to
become overloaded due to the extra work, eventually failing [8]. Early signs of diabetes induced
kidney failure is detected when protein is found in urine [8].
ESRD has an impact on morbidity and mortality of the patients as evidenced by
increasing risk of hospitalizations and long term complications, including cardiovascular disease,
malnutrition, and chronic inflammation [9]. The risk for cardiac events in the ESRD population
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that receive treatment is approximately 3.5 to 50 times higher than the general population [9].
The determinants of cardiovascular disease in this population include family history,
hypertension, diabetes mellitus, dyslipidemia, and obesity [9].
Co-morbidities lead to an increased mortality risk in the general population, though the
effects of these conditions react differently for those on chronic hemodialysis. Ikizler et al. noted
that traditional risk factors towards mortality in the ESRD population appear to be disregarded
when compared to the normal, healthy population. For example, low serum cholesterol usually
associated with decreased risk of mortality in the general population is shown to be associated
with higher rates of cardiovascular morbidity in the ESRD population [9].

High body mass

synonymous with increased mortality in the general population has been shown to be protective
in the ESRD population [9]. Researchers have been forced to explore nontraditional risk factors
attributing to morbidity within the ESRD population. These factors which include anemia,
disturbance in mineral metabolism, oxidative stress, chronic inflammation, and uremic
malnutrition [9].

Chronic inflammation, oxidative stress, and malnutrition are especially

important in the clinical outcomes of the ESRD population [9] since they can affect body
composition. Interestingly, oxidative stress can increase inflammation within the body, which is
caused by a buildup of toxins and decreased antioxidant intake stemming from malnutrition [9].
Inflammation can cause an increase in resting energy expenditure (REE) [10]. Gradually the
body is forced to rely on its own protein stores to attenuate the energy deficit (net protein
catabolism), thereby causing a breakdown of muscle/lean body mass [9], [11] (Figure 1.4). Since
the body has low energy intake and increased energy expenditure, it would rely on its own stores
to make up that deficit which forces the body to waste away, resulting in a net protein catabolic
state known as Protein Energy Wasting (PEW) [10].
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The process of inflammation has been found to be associated with vascular disease in the
general and dialysis populations [12], [13]. It had been found that specific cytokines such as
interleukins are known to induce anorexia or a decrease/suppression in appetite [9], [12]. Toxins
such as advanced glycation end products (AGE), that result from glycation reactions during
glomerular filtration, builds up and therefore lowers defenses against oxidative injury [12].
These AGE also activate mononuclear cells such as lymphocytes that triggers an inflammatory
response [12], also inducing appetite suppression. It is possible appetite suppression occurs by a
decrease in the hormones, leptin and ghrelin [11], that are responsible for controlling the
patient’s appetite. As a consequence, a decreased intake of energy and nutrients (including
antioxidants) results [12], [13].

Cytokine and toxin buildup, coupled with a decrease in

antioxidant intake, resulting in oxidative stress which further increases inflammation within the
body [9].
Other sources of inflammation emanate from dialytic factors. Back filtration allows
molecules such as endotoxins transported via dialysis fluid to end up in the blood due to highflux dialyzers [14].

This triggers an immune response.

Bio-incompatibility of dialysis

membranes increases inflammatory factors within the dialysis patients through activation of
mononuclear cells and white blood cells which are both adaptive responses the body has during
an immune reaction, in addition to the activation of acute-phase responses (e.g. stimulation of
cytokines, interleukins) [12].
Co-morbid conditions induce inflammation in ESRD patients. Infections are common
among hemodialysis patients because they pose a risk due to impaired immunity or vascular
access [12]. Sources of infections stem from septicemia in diabetic patients due to low albumin
levels, imperfection among dialysis grafts, and overlooked skin lesions due to diabetic
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neuropathy of all which trigger an immune response [12] thereby increasing the rate of
inflammation within the body[12], [13]. Moreover, uncontrolled blood glucose can give rise to
non-enzymatic reactions of proteins (during the increase of AGE products) [12] can also trigger
an immune response. During CVD, pro inflammatory cytokines are highly associated with this
and can further increase oxidative stress in addition to inflammation within the body [12], [15].
Malnutrition is common in cases of CKD. Several researchers have reported on the
prevalence of wasting among patients who have ESRD, especially those on hemodialysis [11].
Conversely, uremia is characterized by a buildup of waste products within the bloodstream [4].
Based on previous findings, this buildup of waste products stemming from ESRD complications
is one of the main causative factors that primarily contribute to (uremic) malnutrition since it can
affect nutrient intake due to inflammation. This wasting phenomenon had been defined as a
consequence due to insufficiency of food intake with an increase in energy expenditure, resulting
in a negative energy balance which ultimately causes the body to waste away [11].
CVD is a clinical outcome that is common in ESRD patients due to the increase in
mortality risk [15]. The ESRD patients are also at risk for hospitalization due to poor nutritional
status and inflammation stemming from dialysis and co-morbid related issues [15]. Malnutrition
and inflammation play a role in mortality since they impact nutritional and inflammatory
markers that link CVD with ESRD. This may suggest that ESRD patients should be encouraged
to control aforementioned complications in order to sustain health maintenance.
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Figure 1.0: (a) Kidney anatomy; (b) Path of blood flow through renal blood vessels;
(c) Three major renal processes within the nephron	
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(b)
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and Physiology, 9 Edition, 2012]
The kidneys process an enormous volume of blood each day.
	
  

Of the approximately 1200 ml of blood that passes through the
glomeruli each minute, some 650 ml is plasma, and about onefifth of this (120–125 ml) is forced into the glomerular capsules
as filtrate. This is equivalent to filtering your entire plasma volume more than 60 times each day! Considering the magnitude
of their task, it is not surprising that the kidneys (which account
for only 1% of body weight) consume 20–25% of all oxygen
used by the body at rest.
Filtrate and urine are quite different. Filtrate contains everything found in blood plasma except proteins. Urine contains
unneeded substances such as excess salts and metabolic wastes.
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Figure 1.1: Adjusted Prevalent Rates of ESRD and the Annual Percent Change.

Adjusted	
  Prevalent	
  Rates	
  of	
  ESRD	
  
and	
  Annual	
  Percent	
  Change

Note: The adjusted rate of prevalent cases of end-stage renal disease rose 2010 to 1,763 per million
population, about 21 percent higher than that seen in 2000. The symbols represent the percent changed
from the previous year’s rate.
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Figure 1.2: Stages of glomerular filtration rate (GFR)

Note: units for GFR are expressed in ml/min/1.73 m2; adapted from United States Renal Data System
2012
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Figure 1.3: GFR categories in Chronic Kidney Disease

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
Note: Relative to young adult level. In the absence of evidence of kidney damage, neither GFR category
G1 nor G2 fulfill the criteria for CKD. Adapted from KDOQI Guidelines, 2012: International Society of
Nephrology
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Figure 1.4: Causative factors and outcomes of kidney disease and co-morbidities.
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CHAPTER 2: BACKGROUND AND RATIONALE OF THE STUDY
Renal disease is associated with a range of complex alterations to metabolic functions,
which has an effect on physiological attributes [16]. These issues (e.g. diabetes, infections, toxin
buildup) had been previously shown to be pro-inflammatory [9]. It was later noted that
inflammation negatively affected the body which lead to malnutrition and eventually PEW from
the combination of malnutrition and increased energy expenditure [9].
Methods of intervention are aimed at reducing mortality and morbidity stemming from
CVD in the ESRD population. Previous research has established that causative factors subjected
the body to inflammation and oxidative stress [9], [12]. Dietary intervention was thus aimed at
combatting the complications that were attributed to inflammation and oxidative stress. These
interventions explored anti-inflammatories and antioxidants as possible forms of diet therapy.
A study by Kaysen et al. [12] noted that chronic inflammation among ESRD population
increases pro-inflammatory biomarkers (i.e. interleukins) that are known to induce anorexia
(appetite loss) by suppression of nutrient intake. Thus an ESRD patient with inadequate nutrient
intake is not consuming foods that have a high content of anti-inflammatories or antioxidants.
The low nutrient intake is not enough to offset the damage caused by ESRD complications.
Both anti-inflammatories and antioxidants work by attenuating the buildup of markers
responsible for oxidative stress and inflammation stemming from CVD and dialysis related
factors. Under a high prevalence of oxidative stress stemming from an imbalance of an oxidantto-antioxidant ratio, this increases the amount of oxidative damage [9]. Additionally, uremic
conditions from toxin buildup in the blood also give rise to this imbalance [4]. Interestingly,
serum albumin has anti-oxidant capabilities based on the fact that it is a free radical scavenger
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and a toxic compound-binding agent, which are figures prominently in uremic environments
[17]. This coincides with dialysis patients having a deficit in serum albumin [9]. In the presence
of CVD, pro-inflammatory cytokines are secreted which are an indicatior of rising inflammation
in ESRD patients [18] (responsible for decrease nutrient intake and the eventual PEW). The
anti-inflammatory would thus be aimed at lowering the increase in cytokines [9], [18].
One possibility in the hemodialysis population involved administering Omega-3
supplements (due to their cardio-protective properties) [19]. Dietary sources of omega-3 PUFAs
are anti-inflammatory and also offer benefits for improving lipid profiles, decreasing oxidative
stress, and blood pressure [20]. Thus a combination of protein and Omega-3 supplementation
was evaluated (against a placebo) for its ability to improve inflammation and nutritional status
(the omega-3 as the anti-inflammatory and the protein supplement to attenuate the loss of protein
stores).

However, despite a marginal improvement in triglycerides, serum albumin levels were

unaffected while no changes were observed in the normalized protein nitrogen appearance values
and body mass index values [19].
More research is needed to combat complications associated with ESRD including
malnutrition and PEW since they lead to increased mortality risk. Omega 3 and protein
supplementation has been examined, however, the results are not conclusive [19]. Vitamin E
exists in two forms that differ from each other chemically and in terms of their biological activity
[21]. The two forms tocopherols (TP) and tocotrienols (T3), vary according to the characteristics
of the side chain [21]. Most documented studies on vitamin E refer to TP, which is commonly
used in research and sold commercially as supplements [21]. Tocotrienols are more potent than
TP in terms of biological activity: antioxidant capabilities are more potent than TP and their antiinflammatory effects were found to inhibit the secretion of biomarkers such as IL-6 [21], [22].
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Tocotrienols are part of the vitamin E family [23], [24]. As shown in figure 2.1, they are
molecularly similar to TP and contain a chromanol ring, a hydroxyl group that has the ability to
donate a hydrogen atom [25] and a farnesyl tail, which is hydrophobic. The only difference
between the two forms is the side chain on the T3 contains 3 double bonds at carbon number
three, seven, and eleven, giving them a bent configuration [26].

T3 molecules have four

isoforms: alpha, beta, gamma, and delta, which are determined by methyl group placement on
the chromanol ring an vary in biological activity [23]. Tocotrienols circulate with the aid of a
transfer protein [21], [27]. Though it has affinity for alpha-TP, they are still detected within
plasma at very low concentrations [21], [27]. Postprandial studies of T3 reveal that in plasma
delta-T3 peaked at approximately four hours and alpha/beta was at five hours after oral intake
[28]. Size and mass of T3 are an average of 736.3 angstroms and 410.6 g/mol, considerably less
than TP [25].
Tocotrienols are found in a vast array of foods, although the concentration is low
compared to TP. Currently, majority of supplements containing vitamin E are primarily TP [24].
Tocotrienols are abundant in rice bran, wheat germ, oats, and palm fruit [24]. In fact, the oil
extracted from palm oil has the highest concentration of T3 compared to other plant based
sources [24]. Figure 2.2 summarizes the quantity of T3 listed from plant based sources [24].	
  
Limited studies have discussed the benefits of T3 [29].

Although T3 may not be

abundant based on low transfer protein affinity, the concentration is small enough for beneficial
effects [26]. Beneficial effects of T3 spans across a multitude of attributes, however, anti-oxidant
and anti-inflammatory properties are most notable.

The molecular structure of the T3,

specifically the chromanol ring, contains a hydroxyl group that donates the hydrogen ion to
scavenge reactive oxygen species and free radicals, a prominent effect of its anti-oxidant
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capabilities [26]. T3 also induces other enzymes such as superoxide dismutase or glutathione
peroxidase that takes up free radicals generated by environmental damage or oxidative stress
[29].
Benefits of T3 are still under investigation. So far, T3 has been shown to be cardioprotective and anti-cancer. In some studies, T3 was detected among low density lipoproteins
(LDL) while in transit and later found to prevent oxidation of those molecules [26]. Other
cardio-protective attributes include T3’s ability to inhibit HMG-CoA reductase while
suppressing inflammation [29] thereby reducing the patient’s LDL cholesterol. With regards to
cancer, a rat study showed that mammary carcinogenisis was prevented by way of blocking
chemically induced tumorigenesis of the mammary glands [26]. It noted that T3 suppressed
cells’ proliferation and perhaps induced apoptosis within the tumors [29].
The complications that stem from ESRD, dialytic factors, and co-morbidities subjects the
body to inflammation, toxin buildup, and oxidative stress that ultimately leads to decreased
nutrient intake, malnutrition and an eventual PEW [9]. It appears that T3 may be able to
counteract the inflammation and oxidative stress based on its anti-inflammatory properties. An
increase in pro-inflammatory cytokines may be inhibited, radicals produced during oxidative
injury would be scavenged, and the oxidant-antioxidant ratio would improve to boost the overall
antioxidant defense mechanisms.

Therefore, an ESRD patient on hemodialysis would lower

their mortality risk based on the stabilization or inhibition of complications associated with the
aforementioned factors.

Figure 2.1: Molecule of Vitamin E
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Adapted from: National Center for Biotechnology Information at the National Institutes of Health.
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Figure 2.2: Quantity of tocotrienols listed from plant based sources.

Adapted from www.tocotrienols.org
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CHAPTER 3: OBJECTIVE
The primary objective of this study was to evaluate the nutritional status of the
hemodialysis patients and to see if intervention with T3 supplements had any effect on their
status. This was viewed based on probable change to the patients’ anthropometric measurements
and biochemical profiles. Complications of nutritional status such as PEW, the depletion of
body mass, can be accounted for in BMI since that is a measure of lean body mass [9]. It had
been established that reduced kidney function, dialytic factors, and co-morbidities raise
inflammation which increases energy expenditure while depleting the body stores due to
inadequate nutrient intake [9]. The effects of inflammation cause a decrease in appetite, thereby a
decrease in nutrient intake resulting in a protein catabolic state of PEW since there was nothing
to attenuate an increase in energy expenditure [9], [11].
The nutritional status of the patients on hemodialysis required a diet assessment so that
the recall tracked the nutrient intake. Another value to the diet recall allowed the detection of T3
intake from foods consumed based on previous research. The supplementation of T3 was also
taken into account so that the total intake was determined. Another aspect the research was
analyzing the biochemical profile of serum albumin. Albumin’s role is used to assess protein
status, also known as visceral protein concentration [9]. Other biochemical profiles required to
assess inflammatory status relies on the cytokine or interleukin concentrations [9].
There have been a limited number of studies that evaluate the effects of dietary
intervention

as

seen

in

the

Kuhlmann

et

al.

that

discussed

anti-inflammatory

diet/supplementation and reducing CVD risk. With respect to hemodialysis studies, we know
that mortality risk is reflected in the presence of vascular disease [30] and an increase in PEW
due to malnutrition and inflammation [10], ultimately encompassing CVD [9].
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A connection had been established which states that PEW and mortality is reflected in
serum albumin concentrations, as discussed by Jadeja et al. Diagnosis is often reflected in a
comparison between nutritional requirements in CKD such as total caloric and protein
requirement in accordance with the National Kidney Foundation’s Kidney Dialysis Outcome
Quality Initiative (KDOQI) guidelines (between 0.6-1.2 grams of protein/kg body weight
depending on CKD stage and 30-35 kcal/kg body wt). There are no official recommendations on
supplementation because the studies recommend the importance of protein and energy
consumption while putting some emphasis on consumption of micronutrients such as
antioxidants, vitamins, and certain minerals. The object is to attenuate the loss in protein stores
due to renal disease and complications associated with dialytic factors co-morbidities.
Under the main outcome measures, the use of clinical profiles was required.

This

entailed a recording of nutrient data so that nutrient consumption was determined, in addition to
tocotrienol consumption via food intake.

Nutritional focused physical findings were also

required such as anthropometric measurements of BMI and body weight that provided a visible
outcome to nutritional problems.

Finally, biochemical profiles were analyzed from blood

samples which allowed the researchers to determine serum albumin to asses visceral protein
concentrations (must be around 4 g/dL according to KDOQI guidelines) [9] which is a good
predictor for mortality [3]. These are non-traditional factors whereas traditional risk factors for
mortality tend to be opposite in ESRD patients (low serum cholesterol as a high risk factor for
mortality) [9] and modifiable factors may not be applicable to the ESRD population compared to
the normal population [9].
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CHAPTER 4: MATERIALS AND METHODS

This project involved a collaborative effort of both Wayne State University Nutrition and
Food Science and the Great Lakes Dialysis Center in Detroit, Michigan. The study’s patients
received routine hemodialysis treatment 4 days a week from the Great Lakes Dialysis Center.
The study conducted was parallel designed, randomized, and placebo controlled. The
parallel design consisted of two groups within this dialysis participant study that were randomly
given two different types of treatment. This clinical trial approach allowed the researchers to
analyze and evaluate the outcomes of both types of treatment.
Under this study design, nutritional intervention of the groups were given either placebo
or supplement capsules that were administered to the patients for dialysis and non-dialysis days.
The key objective for the dialysis days was that it allowed the researchers to have a direct
observation of treatment, making it easier to monitor the patients’ compliance when taking the
capsules. On the non-dialysis days, the patients were provided capsule organizers where each
container had a compartment for each day of the week. These patients were grouped according
to dialysis treatment: Sunday, Tuesday, Thursday, and Saturday; and Monday, Wednesday,
Friday, and Sunday.
The supplements (Carotino, Johor Darul Takzim, Malaysia) were provided to both groups
within the study population consisted of a placebo capsule and the tocotrienol rich fraction (TRF)
capsule. The two groups were designated Placebo and TRF based on the supplements that were
administered. The placebo capsule contents consisted of wheat germ oil that is 0.24 miligrams
of tocotrienols and 0.44 milligrams of tocopherols. The TRF capsule contents consisted of Palm
fruit oil that contained 90 milligrams of tocotrienols and 20 milligrams of tocopherols, for a total
of 110 milligrams of vitamin E. To ensure compliance, the patients under directly observed
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treatment were provided with two capsules during dialysis days three times a week. A weekly
organizer was provided with capsules to be taken on non-dialysis days during the two main
meals. The containers were returned each week and then refilled.
Another aspect of the study design was the 24-hour dietary recall performed by the
registered dietitian. Each patient gave a recall at both baseline and then at week 16. The
Nutritionist Pro software (First Databank, Chicago, IL) was used at the Wayne State University
labs to complete the analysis after manually transcribing the hand-written recalls into the
program. Estimations of portion size and quantity were recorded at the dialysis center and later
transcribed by the Wayne State lab graduate research students. This kept track of the nutrient
(macro and micro) and energy intake for all the participants. The total calories consumed during
both time points, especially at week sixteen, gave an indication of whether or not the patients
were consuming enough energy based on the recommended values. The macronutrients (i.e. fats,
carbohydrates, protein) and the micronutrients (i.e. vitamins, minerals) were provided so that
percentages of the diets were calculated in terms of composition. The data was then analyzed
further utilizing statistical analysis software SPSS. It manipulated the data in order to determine
food intake behavior based on group mean differences that used independent t-tests, chi-square
tests for categorical data, and Pearson’s correlation coefficients for correlation tests between two
variables while significant P-values are <.05.
The 24-hour diet recall contained a very important aspect of the study since it was
necessary that some foods consumed by the patients had naturally occurring tocotrienols.
Previous research conducted by various institutions had determined the content of tocotrienols
contained in processed foods. The tocotrienols are naturally found in oils, grains, and some
animal products like eggs. The Wayne State nutrition labs pooled the data from the various
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resources and created a database to determine the tocotrienol content of the foods [38-43]. Data
was provided in milligrams of tocotrienols per kilogram (or 100 grams) of the food item. This
was calculated according to the actual weight of the patients’ food that determined the
approximate amount of tocotrienols consumed.
Laboratory analysis of blood samples was performed for the patients at baseline and
week 16 which obtained the biochemical profiles of both serum albumin and IL-6. Serum
albumin was analyzed at an external laboratory via standard automated laboratory techniques
(Bromocresol Green assay, Satellite Laboratory Services, Redwood City, CA). IL-6 was
measured via the ELISA method per manufacturer protocol (Thermo Scientific, Cat No.
EH2IL6). In addition to blood sample collection, medical professionals at the dialysis center
recorded anthropometric measurements such as weight and BMI at the dialysis clinic.
In summary, the methods involved with the study for laboratory analysis at week zero
and week sixteen were as follows: blood collection for serum albumin and IL-6 content that was
analyzed for protein content and inflammatory markers; clinical profiles (i.e. body weight, BMI)
that allowed the researchers to determine any fluctuations that may have indicated a decline
(stemming from protein energy wasting); dietary analysis based on 24-hour diet recall was
manually input into the Nutritionist Pro software and tocotrienols were calculated using external
databases to analyze the nutrient intake (both macro and micro nutrients). Information on total
calories, protein, and tocotrienols provided some insight into the possibility of malnutrition.
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CHAPTER 5: RESULTS
Tables 5.1 through 5.10 depict the patients’ clinical characteristics and nutrient intake
data for baseline and week 16. The baseline values were recorded at the beginning of the study.
At the end of the study, a comparison of the data between the two time points was made. The
goal of the TRF supplements administered in comparison to a placebo was to observe a possible
difference in the nutrient, clinical, and biochemical profiles of the patients’ data.
Table 5.2 depicts the clinical characteristics of the study population. The BMI intervals,
in accordance with the Center for Disease Control (CDC), are expressed in terms of kg body
wt/m2. The intervals are as follows: underweight (<18.9), normal (19-24.9), overweight (2529.9), obese (30-34.9), very obese (35-39.9), and morbidly obese (40<). The average BMI for
the study population was approximately 29.5 ± 8.1, which is overweight under CDC guidelines
and an average of the placebo and TRF groups (28.7 ± 8.2 and 30.2 ± 8.1, respectively).
Between the two groups, there was no difference throughout the range. In terms of distribution,
majority of the patients were in the 19 to 29.9 BMI level. This distribution did not change at the
end of the study, as the values were the same; majority of patients fell into the 19-24.9 and 2529.9 ranges. Furthermore, there was no significance at either time point.
The next two measurements in table 5.2 were the biochemical profiles of serum albumin
and IL-6. Serum albumin levels read at an overall average of 3.9 ± 0.3 g/dL. There was no
difference between the placebo and TRF groups at both times. Moreover, nothing was significant
after the t-tests were ran. The three distribution levels were determined by the SPSS software
based on frequencies of levels for the patients. The KDOQI guidelines state that an approximate
value of 4.0 g/dL represents a normal value for the dialysis population, and a significant drop
indicates a decline in protein status further adding to the risk of mortality. It may appear that the
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distribution started off with the majority of patients at 3.8 or less at week zero, but week 16 had
most of them in the 3.9-4.1 range. The placebo group in week 16 had only three people move up
into the 3.9-4.1 and 4.2 groups, however, no change in distribution. The remaining patients were
removed from the study since denoted by the reduction in population from 40 to 36. Since the ttest proved no significance, again, these values did not change.
Biomarkers of inflammatory status, such as IL-6, can be viewed in table 5.2. At the
beginning of the study, the average for the patients was at 6.9 ± 6.7 pg/mL. This translated into
around 7.9 ± 7.9 pg/mL for the placebo and 5.8 ± 5.1 pg/mL for the TRF groups. There was no
variation at baseline between the groups considering their averages were about 2 pg/mL apart
and that there was no significant difference determined by the t-tests. At the end of the study,
these values did not change and still had no significant difference between the groups.
The remaining tables, 5.3-5.10, provide information on nutrient intake and possible
relationships among individual macro and micronutrients in addition to the biochemical and
anthropometric profiles. In table 5.3, the average energy and macronutrient intake was provided
for baseline and week 16 time points based on mean comparisons. As expected, baseline values
should have no significant difference since nutrient data was acquired from the patients before
the supplementation was administered. The average for all patients measured at 2013 ± 727 kcals
per day. This accounts for 2097 ± 848 for the placebo and 1932 ± 585 for the TRF groups.
However, there was no significant difference. This translates into a low kcal/kg body weight
measurement at 25 ± 12 kcal/kg body wt for the average. Again, the two groups had no
significant difference following the t-test even though the placebo group consumed
approximately 27 ±14 kcal/kg body wt and the TRF consumed 23 ± 9. In addition, these
averages are below the KDOQI recommendation of 35 kcal/kg body weight except for the
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patients. Over all, these averages that fall below the recommendations suggest there is presence
of under-nutrition in terms of total calories. At week 16, the average intake was approximately
1807 ± 481 kcal/day. However between the groups, there was no significant difference and
overall no change in comparison to the baseline values.
In table 5.3, protein consumption was tracked but the values did not come up significant.
Even though the baseline average of 94 ± 52 g which is 96 ± 68 g for the placebo and 91 ± 31 g
for the TRF groups. With a p-value of 0.074, it had a tendency to be significant based on the p
value that is greater than .05 but less than .1. Per the KDOQI guidelines (1.2 g/kg body wt), only
the placebo group managed to reach that value at about 1.24 ± 0.77 g/kg body wt. This makes
the overall consumption falls below to the amount of 1.16 ±.62 g/kg body wt when TRF is
factored in as it only had 1.08 ± .42 g/kg body wt. A relatively large standard deviation like this
may explain why the range of protein consumption per bodyweight varies so much. This pattern
remained the same at week 16, no change in numbers and there was no significant difference
between the groups. Overall consumption was 90 ± 51 g, which is 83 ± 33 g for placebo and 95
± 62 g for TRF.
The next macronutrient on table 5.3, carbohydrates, had no significant difference between
the two groups at both time points. Carbohydrate intake for all groups was evaluated at roughly
219 g ± 104 g (220 ± 103 g for placebo and 218 ± 107 g for TRF) at baseline and 202 ± 75 g
(198 ± 65 g for placebo and 206 ± 83 g for TRF) at week 16.
Cholesterol intake, on table 5.3, was valued at an average of 431 ± 335 mg, placebo (448
± 274 mg) and TRF (415 ± 388 mg) groups did not differ because there was no significant
difference. There were unchanged values at week 16 indicated by an average of 397 ± 436 mg
(353 ± 247 mg for placebo and 433 ± 544 mg for TRF) with no significance based on the t-tests.
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Among the remaining lipids, total fat intake for the patients was 89 ± 48 g, which
comprises of 99 ± 57 g for the placebo and 80 ± 36 g for the TRF groups, with a p value of
0.084. The difference between the groups had a tendency to be significant since the p-value is
between .05 and .1. At week 16, total fat intake was at an average of 75 ± 30 g, &1 ± 24 g for
the placebo and 79 ± 34 g for the TRF group, but no significant difference. Saturated fat intake
fluctuated around 31 ± 26 g at baseline (36 ± 18 g for placebo and 29 ± 31 g for TRF), but was
not significant. At week 16, there was no change since the average was 26 ± 23 g (21± 8 for
placebo and 30 ± 30 g for TRF), but they had a tendency to be significant since the t-test’s p
value was 0.076. MUFAs, with a significance of .05, was detected at an intake of 31 g ± 20
overall, which is roughly 36 g ± 24 for the placebo and a lower intake of 27 g ±15 for the TRF
group. Week 16 intake had an average of 24 ± 13 g overall, 23 ± 10 g for placebo, and 25 ± 15 g
for TRF, which had a tendency to be significant (p-value = .067) but again no change. PUFA
intake was the lowest intake for both groups with 18 ± 13 g overall, 19 ± 15 g for the placebo
group, and 17 ± 11 for the TRF group, all with no significant difference. The week 16 values
were at an average of 15 ± 12 g (15 ± 11 g for placebo and 16 ± 13 g for TRF) with no
significant difference.
The next table, 5.4, presents the average intake for the remaining nutrients evaluated for
the study population. Sodium intake at baseline was at an average of 3019 ± 1845 mg for all,
which is 2961 ± 2000 mg for placebo and 2074 ± 1705 mg for TRF, but no significant
difference. Week 16 sodium intake values does not show a change based on the average of 3352
± 1628 mg for all, 3256 ± 1531 mg for placebo, and 3429 ± 1720 mg for TRF, with no
significant difference. These values are above the recommended intake of 2 g per day [31].
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The intake for potassium (see table 5.4) was also not significant. The baseline values are
at an average of 2371 ± 2334 mg, 2295 ± 1115 mg for placebo, and 2371 ± 2333 mg for TRF,
but no significant difference. For week 16, intake was at an average of 2015 ± 919 mg, 1962 ±
961 mg for placebo, and 2058 ± 894 mg for TRF, with no significant difference. Moreover,
potassium intake was well within the recommended intake of 2-3 g/day [31].
Vitamin A intake, well above recommendations [31], was determined at in average intake
of 7371 ± 19372 mg, which is 5524 ± 7415 mg for placebo and 9172 ± 26273 mg for TRF at
baseline. The reason for high standard deviation is that one of the patients consumed a high
amount of vitamin A by eating 16 ounces of liver in one day after reviewing their diet recall.
Moreover, these differences were not significant. At week 16, average intake was 6015 ± 9645
mg, 6377 ± 12115 mg for placebo, and 5718 ± 7193 mg for TRF. Again, there was no
significant difference.
Vitamin C intake (See Table 5.4), a water-soluble vitamin, is at risk for severe depletion
during the dialysis process. It is recommended that there should be an intake 60-100 mg/day to
attenuate this loss [31]. At baseline, the average intake was 99 ± 84 mg, which was about 90 ±
81 mg for placebo and 108 ± 86 mg for TRF. This had a tendency to be significant based on the
fact that the p value (0.064) is between .05 and .1. At week 16, average intake was 90 ± 105 mg,
102 ± 112 mg for placebo, and 80 ± 98 mg for TRF with no significant difference.
Vitamin E-TP (see table 5.4) (tocopherol) intake had no significant difference at baseline
or week 16. The average baseline intake was recorded at approximately 10 ± 10 mg, 9 ± 9 mg
for placebo, and 10 ± 10 mg for TRF. At week 16, average intake was 6 ± 4 mg, 5 ± 3 mg for
placebo, and 6 ± 5 mg for TRF.
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The intake of Total T3s (table 5.4) at baseline was taken before the study began and was
detected at an average of 2 ± 4 mg, 2 ± 4 mg for placebo, and 3 ± 4 mg for TRF with no
significant difference. In week 16, interestingly, the values included supplement intake and were
significant with a p-Value of <.0001. The average intake was 92 ± 91 mg, 2 ± 1 mg for placebo,
182 ± 3 mg for TRF. Dietary T3 intake at week 16 was at an average of 2 ± 2 mg, 2 ± 1 mg for
placebo, and 2 ± 3 mg for TRF.
Another nutrient evaluated in the diet recalls was phosphorous (see table 5.4). Average
baseline intake was 1173 ± 589 mg, 1159 ± 601 mg for placebo, and 1186 ± 585 mg for TRF,
with no significant difference. At week 16, average intake was 996 ± 469 mg, 953 ± 431 mg for
placebo, and 1031 ± 500 mg for TRF. These values appear to be at the recommended level [31].
The remaining nutrient intake, calcium, iron, and dietary fiber, are displayed on table 5.4
and neither one of them had any significant differences at baseline or week 16.

Their

relationships can also be viewed on tables 5.6-5.10 for any (significant) correlations. After
analyzing both the mean values of the nutritional intakes for both time points, there appears to be
little or no difference at all. This applies to the overall values as well as for the placebo and T3
groups.
Table 5.5 depicts the baseline and week 16 macronutrient correlation coefficients. This
data would hold the behavior of certain macronutrient intake patterns in comparison with other
macronutrients. The correlation coefficients that are displayed indicate that the relationship
between the two nutrients is significant.
Total calories have positively correlated with all the macronutrients at baseline and
continued their relationship with all except Saturated Fat and PUFA. Saturated Fat and PUFA
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intake did not have any correlation with Total Calories because the relationship was not
significant. Further examination of protein intake did show a (positive) correlation with all
nutrients except saturated fat and PUFA (at week 16 only) because they were not significant.
Carbohydrates only had positive correlation with total calories and protein at both baseline and
week 16. Total fat intake positively correlated with all the nutrients displayed in table 5.5 except
carbohydrates at baseline and week 16. Cholesterol also positively correlated at baseline and
week 16 with all nutrients except carbohydrates and saturated fat, but only at baseline with
PUFA. Saturated fat only positively correlated with Total Calories at baseline only, with Fat at
baseline and week 16, but only with MUFA and PUFA at baseline. MUFA had positive
correlation Total Calories, Protein, Fat, Cholesterol, and PUFA at baseline and week 16. MUFA
did correlate with Saturated Fat only at baseline. PUFA correlated with Total calories, protein,
Cholesterol, and Saturated Fat at baseline only, and with Fat and MUFA at both baseline and
week 16.
Table 5.6 displays the baseline and week 16 micronutrient correlation coefficients
between Total Calories, Sodium, Potassium, Vitamin A, Vitamin C, Calcium, Iron, Vitamin E
(tocopherols), Phosphorous, Dietary fiber, dietary Vitamin E-T3, and Total T3 (dietary +
supplement). Total T3 at baseline only consists of dietary sources of T3 because supplements
were not administered when the first diet recall was recorded. According to this data, Total
Calories positively correlated with Sodium, Potassium, Calcium, Iron, Vitamin E-TP,
Phosphorous, and Dietary Fiber at baseline and week 16. Total calories also correlated with
Vitamin C only at week 16. The remaining nutrients had no correlation with Total Calories since
they were not significant. Sodium and Phosphorous had a positive correlation at baseline and
week 16, but with Potassium, Calcium, Iron, and Dietary Fiber at week 16 only. Potassium
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positively correlated with Vitamin C, Calcium, Iron, Phosphorous, and Dietary Fiber at baseline
and week 16. Vitamin A positively correlated with Iron and Phosphorous at baseline and with
Dietary Fiber at week 16.

Vitamin C also had positive correlation Iron, Vitamin E-TP,

Phosphorous, and Dietary Fiber at baseline only. Calcium had additional positive correlation
with Iron, Phosphorous, and Dietary Fiber at both baseline and week 16.

Iron positively

correlated with Phosphorous and Dietary fiber at baseline and week 16, but only with Vitamin ETP at baseline, in addition to the other relationships previously discussed. Vitamin E-TP also
had positive correlation with Phosphorous at baseline and with Dietary Fiber at week 16.
Phosphorous additionally had positive correlation with Dietary Fiber at baseline and week 16
and with Vitamin E-T3 at baseline only. Dietary Fiber, in addition to other nutrients, positively
correlated with Vitamin E-T3 at baseline and week 16. Vitamin E-T3 did not have any further
relationships with nutrients other than what had been mentioned previously because there was no
significance. This applies to all the nutrients within Table 5.6, no presence of a correlation
coefficient means that there was no significance between the two nutrient comparisons.
Table 5.7 contains the baseline and week 16 correlation coefficients between Total
Calories and Protein with anthropometric and biochemical profiles. Based on the data provided
on the nutrient intakes, anthropometric, and biochemical profiles, serum albumin did not have
any interaction with any nutrient intake or biomarker. While further examining relationships IL6 had with nutrients and biomarkers, there was a positive correlation only with dietary T3 which
suggests IL-6 occurrence is higher with an increased intake of dietary T3. At the end of the
study, IL-6 had no correlation with any nutrient or biomarker because they were not significant.
BMI had a positive relationship with protein intake, Triglyceride levels, and a negative
relationship with HDL cholesterol. The latter two are in conjunction with previous literature on
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the kidney disease population stating that high BMI is associated with higher triglycerides or
lower HDL cholesterol [32]. At week 16, BMI continued to have a negative correlation with
HDL cholesterol, agreeing with BMI-HDL relationship in previously established literature.
The following biomarkers were analyzed based on informational purposes to see if there
is any conjunction with lipid profile data.

Total Cholesterol (serum) only had positive

correlation with Triglycerides at week 16, and LDL Cholesterol at both baseline and week 16.
This claim is agreeable with previous literature [32]. Triglycerides negatively correlated with
HDL cholesterol at baseline and week 16, in addition to, LDL cholesterol at week 16 only. HDL
cholesterol also had a negative correlation with LDL cholesterol at week 16, which is already
established in prior literature [32].
Table 5.8 depicts the interaction between macronutrients and biochemical profiles at
baseline and week 16. Based on the data provided, there was no correlation between the
nutrients and the biochemical profiles.

However, there is an additional correlation test

comparing Dietary Fiber with the other nutrient intakes and it was shown that it had positively
correlated with Total Calories and Carbohydrates at baseline and week 16, but negatively
correlated with (dietary) Cholesterol. The latter may suggest that those consuming fiber rich
foods may consume less dietary cholesterol, or vice-versa.
Table 5.9 contains data on the baseline and week 16 interactions between Vitamin E,
biochemical, and anthropometric correlations. The relationship between the biochemical and
anthropometric profiles had already been discussed in table 5.7. Vitamin E-T3 and Total-T3 both
had positive correlation with IL-6 at baseline.
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The final table, 5.10, contained data that depicts the baseline and week 16 correlation
between T3 and macronutrients.

Correlation among the macronutrients had already been

discussed in table 5.5. Between Vitamin E-T3 and the macronutrients, there was negative
correlation with Cholesterol intake at baseline and positive correlation with Saturated Fat at
week 16.
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Table 5.1: Demographics and clinical characteristics of the study population.

Note: All values are presented as mean ± Standard Deviation except for gender and ethnicity.
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Table 5.2: Baseline and week 16 anthropometric and biochemical profile data.

Values in accordance with the Center or Disease Control, kg body weight/(height in meters)2
KDOQI guidelines state that serum albumin equal to or greater than the lower limit of normal range (approx.
4.0 g/dL for the Bromcresol Green Method) is the outcome goal
Note: all values are presented as mean ± standard deviation. P values derived using independent t-test for IL-6; BMI
and serum albumin using χ² for categorical variables for each time point. *All non-significant unless denoted by a
p-value otherwise. Overall there was no change in values from baseline to week 16. The distributions of BMI and
Serum Albumin also remained the same due. It is suggested that caloric intake is the main cause do to the
unlikelihood of increased physical activity. Additionally, there could be limitations to the study based on the fact
that the 24-hour diet recalls were collected and evaluated at 2 time points and therefore unable to assess dietary
activity between the 16 weeks. E.g.: the decline of 3 participants in 16 weeks from the 19-24.9 range could be
attributed to patient disqualification since one is not accounted for if 2 patients experienced an increase in BMI.
1.
2.
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Table 5.3: Baseline and week 16 macronutrient data.

Note: All values are presented as mean ± standard deviation. P-values derived using independent t-tests for each
time point. Protein intake at baseline along with saturated fat and MUFA at week 16, have a tendency to be
significant. Normally this suggests that the p-Value is greater than 0.05 or less than 0.1.
* All non-significant unless denoted by a p-value otherwise.
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Table 5.4: Baseline and week 16 micronutrient data.

1. alpha-tocopherol
2. Combined tocotrienols from food + supplements for week 16 only.
Note: all values are presented as mean ± standard deviation. P-values derived using independent t-test between the
two groups for each time point.
Vitamin C intake at baseline has a tendency to be significant.
* All non-significant unless denoted by a p-value
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Table 5.5: Baseline and week 16 macronutrient correlation coefficients.

Note: Week 16 values are bold face and italicized. E.g., total calories and protein is significant with a
correlation coefficient value of 0.671. Only those with correlation values between the two variables are
displayed. Those with blank fields are not significant and therefore have no correlative relationship.
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Table 5.6: Baseline and week 16 micronutrient correlation coefficients.

1. Vitamin E-T3 is dietary sourced T3
2. Total T3 is a combination of dietary sourced T3 and supplements.
Note: Week 16 are in bold face point and italicized. E.g., total calories and sodium is significant with a correlation
coefficient value of 0.567. Only those with correlation values between the two variables are displayed. Those with
blank fields are not significant and therefore have no correlative relationship.
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Table 5.7: Baseline and week 16 anthropometric and biochemical profile correlation coefficients.

Note: Week 16 values are in bold face point and italicized. E.g., total calories and protein is significant with a
correlation coefficient value of 0.671. Only those with correlation values between the two variables are displayed.
Those with blank fields are not significant and therefore have no correlative relationship. Other notable attributes:
this suggests that BMI increases when triglycerides increase and decreases with HDL cholesterol increases.
Triglycerides decrease with HDL cholesterol increase and HDL cholesterol increase entails an LDL cholesterol
decrease due to cholesteryl ester transfer protein (CETP) activity. These statements are all in accordance that were
established in previous findings.
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Table 5.8: Baseline and week 16 macronutrient and biochemical profile correlation coefficients.

Note: Week 16 values are in bold face point and italicized. E.g., total calories and protein is significant with a
correlation coefficient value of 0.671. Only those with correlation values between the two variables are displayed.
Those with blank fields are not significant and therefore have no correlative relationship.
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Table 5.9: Baseline and week 16 Vitamin E, biochemical, and anthropometric correlation coefficients.

1. Vitamin E-T3 is dietary sourced T3.
2. Total T3 is a combination of dietary sourced T3 and supplements.
Note: Week 16 values are in bold face point and italicized. E.g., total T3 and Vitamin E-T3 is significant with a
correlation coefficient value of 1.000. Only those with correlation values between the two variables are displayed.
Those with blank fields are not significant and therefore have no correlative relationship.
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Table 5.10: Baseline and week 16 Vitamin E and macronutrient correlation coefficients.

1. Vitamin E-T3 is dietary sourced T3.
2. Total T3 is a combination of dietary sourced T3 and supplements.
Note: Week 16 values are in bold face point and italicized. Only those with correlation values between the two
variables are displayed. Those with blank fields are not significant and therefore have no correlative relationship.
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CHAPTER 6: DISCUSSION
The focus of this study is to analyze the nutritional status of patients with ESRD
undergoing hemodialysis. Specifically, to study the effect of a prescribed vitamin E supplement
on complications of ESRD of these patients. ESRD is the result of CKD after a gradual loss in
kidney function as the rate at which blood flows through the glomeruli to filter out byproducts,
falls to less than 15 mL/min/1.73m2[1]. A buildup of waste products in the blood damages the
blood vessels (also known as nephropathy). This causes the kidneys to fail, which makes
hemodialysis as a form of renal replacement therapy necessary. Prevalence of ESRD has been
on the rise since the 1980s according to the USRDS. ESRD afflicts a certain number of
Americans, especially African Americans who constitute 33% of the 400,000 patients seeking
dialysis treatment. ESRD continues to be the highest for African Americans compared to other
ethnicities [2], [3]. However, between mortality and survivability, certain factors show the
African American dialysis patients have a greater survival rate than Caucasian patients

[1](e.g.

body mass, lipid profiles) [2].
Based on current research, causes of CKD and ESRD stem from multiple factors. Drug
use can affect intra-glomerular blood flow, lead to cell injury via cytotoxicity, and cause crystal
induced obstruction of the vessels [7]. During hypertension, high blood pressure forces the heart
to work harder over time, thereby damaging blood vessels throughout the body, including blood
vessels within the kidneys [8]. Those inflicted with diabetes have higher levels of blood sugar
that causes the kidney filters to become overloaded due to the extra work, eventually failing [8].
Early signs of diabetes induced kidney failure is detected by protein found in urine [8]. As a
result, ESRD has an impact on morbidity and mortality of the patients as evidenced by increasing
risk of hospitalizations and long term complications, including cardiovascular disease,
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malnutrition, and chronic inflammation [9].

The risk for cardiac events is higher in this

population, thereby contributing to their risk of mortality [9].
Researchers have been forced to explore nontraditional risk factors contributing to
morbidity within the ESRD population. Ikizler et al. noted that traditional risk factors towards
mortality in the ESRD population appear to be contrary to effects in the normal, healthy
population. For example, low serum cholesterol is protective in the general population but
opposite in the ESRD population, and high body mass which is normally a risk factor in the
general population is protective for those with ESRD [9]. Other risk factors contributing to
morbidity in ESRD patients include anemia, disturbance in mineral metabolism, oxidative stress,
chronic inflammation, and uremic malnutrition [9]. Chronic inflammation, oxidative stress, and
malnutrition are especially important in the clinical outcomes of the ESRD population [9] since
they can affect body composition.
One of the major issues that is associated with dialytic and ESRD related conditions, is
the amount of inflammation the body endures. Inflammation can stem from multiple origins,
including vascular disease [12], [13], dialytic factors (e.g. incompatible dialyzer membranes,
reduced kidney function), and co-morbidities (e.g. infections) [9].

Other sources of

inflammation can result from uremic toxin buildup [4]. Interestingly, oxidative stress too can
increase inflammation within the body, which is caused by a buildup of toxins and decreased
antioxidant intake stemming from malnutrition [9]. It has been found that specific cytokines
such as interleukins (IL-6) were found to be present during inflammation in addition to the
accumulation of AGE products [9], [12]. This eventually lowers antioxidant defenses (e.g.
serum albumin [9], [17]) against oxidative injury in addition to the suppression of appetite
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(anorexia), which causes a decrease in nutrient intake (malnutrition), especially antioxidant
intake [9], [13]. Additionally, inflammation has also has been found to increase REE [9].
Malnutrition and chronic inflammation have been found to be direct results of
multifaceted effects of dialytic and co-morbid conditions. This ultimately leads to strong clinical
outcomes and increased mortality risk [11], [12]. Ikizler et al. provided a systemic approach to
the effects and root causes surrounding malnutrition and inflammation discussed in figure 1.4.
These inflammatory responses to ESRD complications were found to have caused a reduction in
appetite and further increased energy expenditure denoted by an increase in REE [9]. This
becomes a net catabolic protein state in which the body is forced to rely on its own protein stores
for energy, resulting in a loss of body mass, also known as PEW [11], [10].
CVD is a common clinical outcome in ESRD patients due to the increase in mortality risk
[15]. The ESRD patients are also at risk for hospitalization due to poor nutritional status and
inflammation stemming from dialysis and co-morbid related issues [15].

Malnutrition and

inflammation play a role in mortality since they impact nutritional and inflammatory markers
that link CVD with ESRD. This may suggest that ESRD patients should be encouraged to
control aforementioned health complications in order to sustain health maintenance.
The objective of this project was to evaluate nutritional status of hemodialysis patients
while undergoing an intervention of T3 supplements.

The effects can be viewed through

probable changes to the patient’s anthropometric (BMI) and biochemical profiles (serum
albumin, IL-6). The anti-inflammatory characteristic of T3 is a key component by way of
attenuating the effects of damage brought forth by inflammation where it may combat the rise in
inflammatory markers. Additionally, many improvements have been made on the oxidantantioxidant ratio, attenuation to the loss of serum albumin, as well as the possible defense
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towards prevention of inflammation. Many components of inflammation stem from decreased
renal function, dialytic factors, and co-morbidities (i.e. diabetes, CVD, infections) [13], [12], [9].
Moreover, the properties of T3 could potentially attenuate the loss of albumin as an antioxidant
defense mechanism, thereby restoring the oxidant-to-antioxidant ratio to a normal level.
Additionally, the immune response is a form of an acute phase response that triggers the
stimulation of cytokines and interleukins, which can reduce antioxidant levels [12], thereby
inducing oxidative damage. Tocotrienols allow the hydroxyl group that donates a hydrogen ion
to later scavenge reactive oxygen species and free radicals, which is one of its prominent antioxidant capabilities [26]. Another antioxidant property of T3 is the induction of other enzymes,
such as superoxide dismutase or glutathione peroxidase, that take up free radicals generated by
environmental damage or oxidative stress [29].
Records of dietary intake and blood samples were taken and evaluated at two time points:
baseline (Week 0) and Week 16. Changes in biomarkers and nutritional status were observed.
Nutritional status is based on both macro and micro nutrient intake and compared to the NKF’s
KDOQI guidelines.
As mentioned before, anthropometric measures were observed at the beginning and the
end of the study. This allowed the researchers to see whether nutritional status had any impact
on the measurements while T3 supplements were prescribed. It appears that no change was
detected in the patients’ BMI. There was no change in the average BMI values of both study
groups (roughly 30 kg/m2, 29 kg/m2 for placebo, and 30 kg/m2 for TRF), as well as in the
distribution (the majority of patients were in the 19-24.9 and 25-29.9 ranges) at both time points.
Moreover, it appears that the decrease in patients from the second interval may be partly due to
the reduction in patients from the study. One will also notice that the number of participants is
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lower in week 16 compared to baseline. BMI did have a positive correlation with protein intake
at week zero, considering the relationship between protein and body mass and how the body
requires protein intake to build muscle. At the end of the study, there was no significance
between BMI and protein, suggesting that there is no correlation at all. In other words, there was
no change in the data and no way to determine if PEW among the patients is present due to the
unchanged BMI values compared to nutrient (energy and protein) values at the end of the study.
There were additional results pertaining to BMI’s relationships. During the correlation
tests, BMI negatively correlated with HDL cholesterol (table 5.7) suggesting that high BMI
entails low HDL cholesterol, which agrees with previously established literature [33]. Other
notable observations, which agreed with current literature, were the positive correlation between
BMI and triglycerides, positive correlation between total cholesterol and triglycerides, negative
correlation between HDL cholesterol and triglycerides, and the positive correlation between LDL
cholesterol and total cholesterol [33].
The biochemical profiles of serum albumin and IL-6 were observed to indicate possible
changes in nutritional and inflammatory status [9], respectively. Any decrease in serum albumin
or increase in IL-6 could raise mortality risk [5], [3], [9]. It is reported that no changes were
detected in serum albumin or IL-6. Most patients remained in the <3.8 g/dL and 3.9-4.2 g/dL
ranges at both time points. There was not any relationship between serum albumin and the
individual nutrients when correlation tests were run. Moreover, IL-6 values were insignificant at
an average of 6.9 pg/mL (7.9 pg/mL for placebo and 5.8 pg/mL for TRF). These values did not
change at week 16 indicating no effect on inflammatory markers. There was some slight positive
correlation with food-sourced T3, however, the study was to determine the effect of total T3
administered to the patients and therefore this was disregarded. At the end of the study there was
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no significant change due to any of the nutrients. This may not be enough to state whether or not
mortality risk has been affected in favor of lessening the risk or that there is a basis for IL-6
induced protein energy wasting [8].
One of the main points the study was trying to investigate was whether there was a
presence of malnutrition detected in the nutrient intake of the patients. Interestingly, since the
nutrient data was recorded at two time points starting at week zero and then week 16, the
numbers should have indicated malnutrition based on the comparison with the United States
Renal Data System (USRDS) data or other cohort hemodialysis studies.
The values for total calories consumed per kilogram of body weight were 27 kcal/kg
body weight versus USRDS recommended 35 kcal/kg body weight. One can see that these
values fell below the USRDS recommendations. This remained unchanged at the end of the
study as well. It does not appear that the T3 supplements have had an effect on nutrient intake or
appetite considering energy intake has remained the same at both time points. Moreover, the
numbers may also appear lower; p-values were not significant, and therefore no significant
difference existed between the caloric intakes between the two groups.

These values that

represent the study population are inadequate, meaning that population size or compliance may
have played a factor in the t-test results.
After analyzing the protein intake, it appears that there was no change in intake over the
course of the 16-week study. It started off approximately 18-19% of the meals, but remained the
same (from an overall of 94 ± 52 g to 90 ± 51 g) at the end of the study. After analyzing the
consumption patterns, it increased along with the consumption of other nutrients such as
carbohydrates, fat, cholesterol and MUFA. There was no significant difference between the
groups at both time points and the protein consumed by body weight also was unchanged. NKF
	
  

	
  

50	
  

KDOQI guidelines recommend hemodialysis patients consume more than 1.2 g/kg body wt,
which only the placebo group (1.24 ± 0.77 g/kg body wt) has at both time points. The patients in
the TRF groups were consuming less than that recommended amount and are at risk for proteincalorie malnutrition and hypoalbuminemia [10]. It was recommended that HD patients consume
protein that comprises ≥15% of the diet, which the study population appears to have achieved.
However, the total energy intake does not reflect the individual protein intake. There may have
been inaccuracies with the diet recall, issues with the population size, or non-significance of the
values may have produced these results.
Carbohydrate was the nutrient that comprised 42-45% of the diet. As this was between
baseline and week 16, not much difference between the. It should be about 50-60% of the diet
[31], which the study population was not able to meet. This could also explain why the caloric
density intake is below the KDOQI recommended 35 g/kg body weight. Average fiber intake
was around 13 mg at baseline and week 16. Both groups did not meet the recommended intake
of an estimated 20-25 mg [31]. As suggested by previous literature, the problem with a low fiber
intake is that it can negatively affect lipid levels [31]. One interesting point that appears to stand
out is the fact that baseline fiber intake decreased as cholesterol intake increased after analyzing
the correlations in table 5.8. This suggests that the inverse relationship could be explained by the
lipid lowering effect fiber has during consumption that is suggested in previous literature.
However, cholesterol intake was higher than expectations thereby suggesting the opposite and
setting the patients up for heart disease. The food choices many patients made were comprised
of refined or simple carbohydrates instead of complex variety such as fiber.
Lipid intake in this study population reflects a diet that promotes an increased heart
disease risk. Cholesterol intake of the patients exceeded the American Heart Association (AHA)
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recommendation of <300 mg/day.

This intake may subject the patients to hyperlipidemia

according to the AHA, and given their current health state, the risk for mortality is greater. The
high cholesterol intake is mainly due to the frequency of egg consumption as seen on the diet
recalls. When it comes to Total Fat intake, the patients consumed a diet that is comprised of 3640% of it. Moreover, Saturated fat comprised 14% of the diet and unsaturated fat was about
22% (MUFA-14%, PUFA-8%) at baseline. At week 16, the diets were 13% saturated fat and
19% unsaturated fat (MUFA-12%, PUFA-7%). Interestingly, MUFA and Saturated fat had a
tendency to be significant since the p-value was between 0.05 and 0.1. The values may have a
tendency to reflect the intake in both groups and a slight difference. However, there may have
been factors that caused the statistical analysis test to come up non-significant (e.g. inaccurate
diet recall), which is why certain nutrients that are not accounted for in the total caloric intake.
According to AHA, the study population did not meet their recommendations. The
patients exceeded the recommended intakes for total fat and saturated fat [31] thereby increasing
their risk for heart disease. This could be viewed in the correlation studies (see table 5.5) on how
total fat and saturated fat positively correlated with Total Calories. This means that the intake of
both increased while there was an increase of Total calories.
Along with macronutrient intake, micronutrients were tracked as some are held in high
importance to the ESRD population (e.g. sodium, potassium, phosphorous, Vitamin A, Vitamin
C). The majority of micronutrient consumption in the study did not change from baseline to
week 16. Towards the end of the study, there was no significant difference between the groups.
When sodium intake was detected at averages around 3000 mg per day, it exceeded the
recommendations of <2000 mg [31]. It appears to be cumbersome for the patients since sources
of sodium are primarily dietary-based or found in dialysate [34]. Potassium intake remained at
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around 2000 mg at baseline and week 16, therefore exhibiting no change. Both groups’ values
had no significant differences. When it was compared to other dialysis studies, it exceeds their
recommended ranges as well [31].

Tracking its behavior with other nutrients, potassium

increased with increases in Total Calories, sodium intake (week 16 only), vitamin C, calcium,
iron, phosphorous, and fiber. Sodium intake increased along with the following nutrients (table
5.6): Total Calories and Phosphorous at both time points, and with Potassium, Calcium, Iron, and
Fiber at week 16. Based on these observations, the foods frequently consumed contained these
common nutrients.

Since t-tests did not prove significance, it may explain why these

micronutrient intakes are not consistent with caloric intake. Moreover, the results of other
studies have shown high potassium intake associated with increased death or survival hazards
[35]. It can be in part due to issues like hyperkalemia caused arrhythmia [31]. High sodium
intake concurrent with hypertension in normal population is more problematic in the kidney
disease population since CVD is associated with complications leading to greater mortality [34].
Based on these numbers, the study population managed to keep potassium intake under control.
However, the validity of the results may be questionable considering the study limitations which
is viewed in the t-tests.
Phosphorous intake is of high importance to the ESRD population.

Patients are

encouraged to consume low amounts through diet and take binders since it is also affects calcium
levels within the body [36]. Other important attributes in the CKD population is the awareness
of soft tissue calcification associated with CVD risk [36]. Baseline and week 16 intake was
between 950-1200 mg. The t-tests proved that there was no significant difference between the
groups at both time points. Phosphorous did correlate with the majority of micronutrients,
including dietary-based T3 at baseline only. The reason for these numbers is that various foods
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consumed by the patients contained large amounts of phosphorous (e.g. beef, chicken, processed
foods, condensed soups). These foods have common nutrients such as phosphorous, which may
be why it had correlated with the intake of other micronutrients. The intake of phosphorous have
been above recommendations at baseline and below them at week 16 [31]. Because there was no
significance, it would be difficult to make that observation on their diet behavior being affected
by their state of health.
The vitamins that were analyzed hold relevancy to the dialysis population. Some of these
micronutrients are fat soluble (e.g. Vitamin A, E) and water soluble (e.g. Vitamin C). The water
soluble vitamins are easily depleted during dialysis [37]. The vitamins that had been analyzed
are all antioxidants and knowing the intakes of each would provide insight into a patient’s
antioxidant status.
Average intake of Vitamin C at baseline and week 16 was about 80-110 mg, which
happens to be within the recommended amount of 60-100 mg [31]. This may not be enough due
to potential reduction in levels during the dialysis process [37], and therefore requires
supplementation. Vitamin C is protective for heart disease because of its antioxidant attributes.
Even though it may appear that Vitamin C had a tendency to be significant at baseline, it is
important to note that the time of this diet recall was taken before supplementation and should
not be different at all. Week 16 values had no significant difference between the groups meaning
that the unchanged values carried over throughout the study.
Vitamin A is another form of anti-oxidant whose levels did not necessarily change in the
16 weeks. The average intake at baseline was around 7400 mg but there was no significant
difference between the two groups. At week 16, even though intake was about 6000 mg, there
still was no difference between the groups. One other interesting point is that one of the patients
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consumed 16 ounces of liver, rich in vitamin A, which explains the unusually high standard
deviation in the baseline TRF group. Based on this study population, it appears as shown in
previous studies that excessive intake of vitamin A does not benefit patients since it has a prooxidant effect [31].
Some of these vitamins appear to surpass the recommendations, however, no significance
may question the validity of their values due to the study’s limitations and how they may not
match with the values concurrent with a dialysis population. This may also explain, for example,
why Vitamin C correlated with micronutrients at certain time points, or why Vitamin A
correlated with few nutrients in question. Vitamin A’s intakes were unusually high given that
overall energy intake was low. Again, it would be difficult to argue this assumption considering
these values were not significant.
The final vitamin, E, has been taken into account due to antioxidant capabilities. Both
tocopherols and T3 were tracked. Tocopherol intake was around 10 mg at baseline and 6 mg at
week 16. There were no significant differences at either time and the data tables also show that
there was not any variation based on those t-test evaluations (which also applied to previous
nutrient evaluations). Only baseline values have met recommended levels, however, there is not
enough justification for the use of tocopherols in the prevention of coronary artery disease [31]
according to the AHA. When the study population’s T3 intake was analyzed, primarily dietary
based at baseline, was marginal since they are between 2-3 mg with no significant difference. At
week 16, one of the groups received supplementation in addition to dietary-based T3 and that is
why there was a large variation of 2-182 mg, which may have explained the significance
between the two groups. It is important to note that tocopherols and T3 share the same transport
protein when in circulation in the body [26] for which tocopherols have a higher affinity.
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Unfortunately, there was not enough evidence based on average intakes and non-significance to
detect a change in the intake of other nutrients due to overlying causes as aforementioned. Also,
the intake at week 16 is primarily sourced from supplements for the TRF group. Other notable
inquiries in the results were that T3 and dietary cholesterol at baseline had a negative correlation,
which means that T3 intake involved a decrease in cholesterol intake. This may be due to T3
rich foods being more prevalent in reference to cholesterol rich foods within the diet. T3 also
increased with saturated fat at week 16, meaning that saturated fat-rich foods may also have
either contained T3s or were eaten frequently with separate T3-containing foods. One interesting
point would be the positive correlation between T3 intake and IL-6 at baseline only. It may be
that the patients consuming T3-rich foods have a higher incidence of IL-6.

Il-6 being a

biochemical marker for inflammation should be decreased after supplementation, however, this
did not happen based on no correlation with T3 intake at week 16. It may be easy to rule out
T3’s ineffectiveness, but the non-significance in baseline values for other nutrients may require
more information or testing.
As one can observe here, the study population has less than required energy and protein
intake, whereas the micronutrient intake varies. Some are below while certain micronutrients are
above recommended levels. This may also explain why the study population’s diet was not
consistent with heart healthy as compared to similar dialysis studies [31]: fat and carbohydrate
intake was not optimal. In addition to the macronutrients, sodium levels were high enough to put
the patients in a hypertensive state. Basically, no discernible effect was detected in terms of
nutrient intake after supplement treatment. Additionally, it could be due to the quality of
analysis based on t-tests or correlations that make no detectable pattern. It would be difficult to
identify signs of malnutrition since the week 16 data did not exhibit significant difference
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between the two groups.

Perhaps it is advisable to disregard the fact that T3 may have played a

role in nutrient intake behavior since almost every nutrient average had no significant difference
between the groups at the conclusion of the study.
Other notable issues that arose during the data analysis of the food intake were a
possibility of inconsistencies with the actual diet recalls. It could be that the diet recalls may
contain some inaccuracy since they are solely based on the patients’ memory. Portion size may
have been exaggerated or that estimation of servings during transcription into the Nutritionist Pro
software may not be accurate.

This could have had some influence on the patient’s diet

composition. Moreover, many foods recorded from patients were not found in the Nutritionist
Pro’s central database and alternatives were used in place of some food items.
The data that was collected on T3 intake through food was pooled from external
resources and their accuracy is questionable. In other words, the data analysis run by SPSS that
gave non-significant results could have been affected by the diet recall or transcription
inaccuracy. This can affect the t-tests and correlations, leading to the conclusion that there was
no change in nutrient data detected when T3 supplements were administered. Other notable
inquiries would be study limitations. Diet recalls were limited to two times and only at the start
and conclusion of the study.
One cannot conclude that T3s are ineffective against stabilizing the complications
attributed to ESRD. One observation showed total calories correlated with some nutrients at
week zero but less at week 16. This produces mixed results and would not be easy to provide
any direct conclusion that T3s had any effect. A future study may want to test with an increased
dose of T3 to compare with previous results and how nutritional behavior may react with a larger
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dose so that optimal levels can be investigated. That, along with a larger population size, would
entail a smaller margin of error.
As one would address the study’s limitations, the logistical issues concerning data
collection would require the researchers to take a more detailed account. Addressing issues with
the effectiveness of a 24-hour diet recall could justify providing patients with their own food
diaries so that they can record their meals immediately after consumption. This would ensure
more accurate reporting of portion size. To address the discrepancy between energy and nutrient
intake, it may be beneficial for patients to receive more extensive nutritional counseling, in order
to ensure compliance with recommended intakes.
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Kidney disease is defined by a loss of kidney function over time [1]. It is expressed in
terms of glomerular filtration rate at five stages calculated by the MDRD formula [5]. The fifth
stage (<15 mL/min/1.73m2) is designed as end stage renal disease requiring renal replacement
therapy in the form of hemodialysis [5]. This requires the use of an artificial kidney (dialyzer) to
filter out by-products from the blood for excretion [8].

The issue arises when toxin

accumulation due to decreased renal function, dialytic factors such as incompatible dialyzer
membranes reacting with blood, and co-morbid conditions such as infection or diabetes mellitus
[3]. This increases inflammation within the body, leading to a negative nutrient/energy balance,
resulting in a loss of body mass thereby increasing the mortality risk [10]. Tocotrienols (T3), a
more potent and underutilized form of Vitamin E, are being administered to attenuate this
increase in inflammation via supplementation in addition to food intake.

A cohort of

hemodialysis patients was analyzed in order to study this issue. The nutritional status was
assessed utilizing three measures: examining nutrient intake profiles (while supplementation was
taken into consideration), obtaining anthropometric findings of body mass index, and analyzing
biochemical profiles of serum albumin and pro-inflammatory markers (i.e. IL-6). This data was
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obtained via a randomized, double blind, placebo-controlled study of 81 dialysis patients. At
two times over the course of 16 weeks, blood collection for serum albumin and inflammatory
markers was analyzed and dietary intake was assessed using 24-hour diet recalls and Nutritionist
Pro software. Statistical analyses of paired t-tests and correlation studies revealed no significant
differences between the two groups later showing no noticeable effect of T3 supplementation.
Reasoning may be multifactorial such as underestimation of food intake, transcription of diet
recalls may not be truly representative, or T3 supplements may not have had an effect on the
nutritional statuses. It may be beneficial for patients to receive more extensive nutritional
counseling as opposed to nutritional supplementation to ensure compliancy with recommended
intakes.

	
  

